Synageva, Alexion deal

Alexion will acquire Synageva for $115 in cash and 0.6581 Alexion shares per Synageva share, or about $9 billion. The offer is based on 38.9 million shares of Synageva outstanding and Alexion’s close of $168.55 on May 5, the day before the deal was announced. Alexion gains Kanuma seblipase alfa, a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy (ERT) that is under Priority Review in the U.S. and accelerated assessment in the EU to treat LAL deficiency (Wolman disease). The PDUFA date is Sept. 8; Alexion expects a decision in the EU next half. ...